Robert Ferland, MD
Family Medicine · Goodlettsville, TNNPI 1447256490
Payments from drug & device makers
Across 332 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$565
- AbbVie$526
- Boehringer Ingelheim$385
- AstraZeneca$373
- GSK$256
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,84999%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,028 |
| Lilly USA, LLC | 41 | $565 |
| AbbVie(2 entities) | 49 | $526 |
| Boehringer Ingelheim | 20 | $385 |
| AstraZeneca | 24 | $373 |
| GSK | 16 | $256 |
| Johnson & Johnson | 14 | $251 |
| Sanofi-aventis U.S. LLC | 13 | $211 |
| Pfizer | 11 | $164 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Novartis | 4 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $95 |
| Supernus Pharmaceuticals, Inc. | 5 | $93 |
| Merck | 5 | $91 |
| Amgen(2 entities) | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Astellas Pharma US Inc | 4 | $62 |
| Eisai Inc. | 3 | $56 |
| Biodelivery Sciences International, Inc. | 3 | $46 |
| Abbott | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Bayer | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Phadia US Inc. | 1 | $13 |
| Vistapharm, Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$4,877 in reported general payments places this provider in the 80th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx SyringeSecukinumab | 11 | $79,239 |
| FarxigaDapagliflozin Propanediol | 112 | $59,550 |
| OzempicSemaglutide | 39 | $40,004 |
| JardianceEmpagliflozin | 49 | $34,946 |
| JanuviaSitagliptin Phosphate | 45 | $29,089 |
| EliquisApixaban | 40 | $25,496 |
| XareltoRivaroxaban | 25 | $21,794 |
| TrulicityDulaglutide | 15 | $14,635 |
| LinzessLinaclotide | 14 | $7,100 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,493 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,366 |
| RivastigmineRivastigmine Tartrate | 79 | $4,233 |
| MyrbetriqMirabegron | 11 | $4,175 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $3,577 |
| Midodrine Hcl | 31 | $1,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $373 | $59,550112 claims |
| Novo NordiskOzempic | $1,028 | $40,00439 claims |
| Boehringer IngelheimJardiance | $385 | $34,94649 claims |
| MerckJanuvia | $91 | $29,08945 claims |
| PfizerEliquis | $164 | $25,49640 claims |
| Johnson & JohnsonXarelto | $251 | $21,79425 claims |
| Lilly USA, LLCTrulicity | $565 | $14,63515 claims |
| AbbVieLinzess, Synthroid | $526 | $8,50027 claims |
| GSKBreo Ellipta | $256 | $6,49317 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $4,17511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Goodlettsville
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.